IFNB1 and myeloid sarcoma: • ≥3 vs. no comorbidities present at MS diagnosis associated with a 25% lower risk (hazard) of starting a DMT (83)• specific comorbidities present at diagnosis - anxiety or ischemic heart disease - associated with a 22-28% lower risk (hazard) of starting a DMT (83)• only the injectable DMTs were studied (IFNB, GA)